Abstract:Objective:To compare the effects of exenatide and insulin aspart 30 injection on carotid intima-media thickness (cIMT) in patients with type 2 diabetes mellitus (T2DM) with different baseline characteristics, and to explore the influencing factors of exenatide in improving atherosclerosis (AS).Methods:A total of 59 patients with T2DM who were admitted to the Department of Endocrinology of Beijing Hospital from March 10, 2015 to June 20, 2017 were enrolled. The study was designed as a randomized, prospective, parallel positive drug control study. According to the baseline cIMT <1 mm and ≥1 mm, the patients were divided into the following groups: baseline non-atherosclerotic group and baseline atherosclerotic group; according to body mass index (BMI)<24 kg/m 2 and ≥24 kg/m 2, they were divided into normal weight group, overweight and obesity group; according to the baseline glycosylated hemoglobin A 1c (HbA 1c)<8.5% and HbA 1c≥8.5%, they were divided into general hyperglycemia group and significant hyperglycemia group; according to the decrease of HbA 1c<1.5% and HbA 1c ≥1.5% at 52th week, the patients were assigned to the general hypoglycemic effect group and the good hypoglycemic effect group. The cIMT was measured. The results of each group were compared by group t test, nonparametric test and χ 2 test. Results:The prevalence rate of carotid atherosclerosis in patients with T2DM was 64.41% (38/59). After 52 weeks of treatment with exenatide, the cIMT of patients with baseline AS was significantly lower than that of patients without baseline AS ( P=0.02). After 52 weeks of treatment with exenatide, the cIMT decreased in overweight and obese subjects, but slightly increased in normal weight subjects, and the difference was not statistically significant ( P=0.21). After 52 weeks of treatment, the cIMT decreased in both the general hypoglycemic effect group and the good hypoglycemic effect group, but the difference was not statistically significant ( P=0.17). After treatment with exenatide, there was no correlation between cIMT changes and blood glucose, low density lipoprotein cholesterol and BMI changes within 52 weeks ( P=0.576, 0.188 and 0.352, respectively). Conclusions:In patients with atherosclerosis at baseline, the improvement of cIMT was more significant and the benefit was greater after the administration of exenatide. cIMT levels were not affected by baseline body weight and hypoglycemic efficacy, and had no correlation with BMI and blood glucose changes after exenatide treatment.

Non-targeted Metabolomic Analysis Predicts the Therapeutic Effects of Exenatide on Endothelial Injury in Patients with Type 2 Diabetes.

Association of Time in Range with Endothelial Injury in Patients with Type 2 Diabetes Treated with Exenatide

Exenatide Exerts Direct Protective Effects on Endothelial Cells Through the AMPK/Akt/eNOS Pathway in a GLP-1 Receptor-Dependent Manner.

1012-P: the Factors Influencing the Changes of Adipocytokines in Patients with Newly Diagnosed T2DM Treated with Exenatide

Efficacy and tolerability of exenatide monotherapy in obese patients with newly diagnosed type 2 diabetes: a randomized, 26 weeks metformin-controlled, parallel-group study.

Efficacy of Exenatide Administered Twice Daily in Body Mass Index Reduction in Patients with Type 2 Diabetes Mellitus

Comparison of the Effects of Twice-Daily Exenatide and Insulin on Carotid Intima-Media Thickness in Type 2 Diabetes Mellitus Patients: a 52-Week Randomized, Open-Label, Controlled Trial

Exenatide Prevents High-Glucose-induced Damage of Retinal Ganglion Cells Through a Mitochondrial Mechanism

Efficacy and Safety of Exenatide in Patients of Asian Descent with Type 2 Diabetes Inadequately Controlled with Metformin or Metformin and a Sulphonylurea

Effect of Exenatide on serum fibroblast growth factor-21 level in patients with type 2 diabetes

Comparing the Effects of Twice-Daily Exenatide and Insulin on Renal Function in Patients with Type 2 Diabetes Mellitus: Secondary Analysis of a Randomized Controlled Trial.

966-P: Effect of Baseline SS-Cell Function on Treatment Response to Exenatide in Patients with Newly Diagnosed Type 2 Diabetes

1938-P: GLP-1 Receptor Agonist Ameliorates Intramyocellular Lipid Deposition Without Weight Loss by Activating AMPK

Exenatide Treatment Decreases Fasting Fibroblast Growth Factor 21 Levels in Patients with Newly Diagnosed Type 2 Diabetes Mellitus.

Exenatide Attenuates Obesity-Induced Mitochondrial Dysfunction by Activating SIRT1 in Renal Tubular Cells

Effects of exenatide and insulin aspart 30 on vascular function in diabetic patients with different baseline characteristics

Effect of Baseline -Cell Function on Treatment Response to Exenatide in Patients with Newly Diagnosed Type 2 Diabetes

GLP-1 Receptor Agonist Improves Mitochondrial Energy Status and Attenuates Nephrotoxicity In Vivo and In Vitro

Effect of Exenatide after Short-Time Intensive Insulin Therapy on Glycaemic Remission Maintenance in Type 2 Diabetes Patients: a Randomized Controlled Trial

Efficacy and safety of exenatide in Chinese patients with type 2 diabetes inadequately controlled with metformin or metformin and a sulfonylurea

Efficacy and safety of domestic exenatide injection in treating type 2 diabetes: A multicenter, randomized, controlled, and non-inferiority trial